An optimized procedure for Luminex-based human platelet antigen-specific antibody screening and identification (PakLx assay) with a cost-effective approach and improved sensitivity.

Background And Objectives: Detection of anti-platelet antibodies is required for the diagnosis of foetal/neonatal alloimmune thrombocytopaenia. The most commonly used methods for anti-platelet antibody detection are the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and the Luminex bead assay (PakLx). However, for economic reasons, the use of the PakLx assay is limited.

Characterization of the novel HLA-DQA1*05:18 allele by next-generation sequencing.

DQA1*05:18 differs from DQA1*05:01:01:03 by one nucleotide substitution at position 94 in exon 2.

Characterization of the novel HLA-DQA1*03:11 allele by next-generation sequencing.

DQA1*03:11 differs from DQA1*03:03:01:01 by one nucleotide substitution at position 664 in exon 4.

Characterization of the novel HLA-DQA1*01:39 allele by next-generation sequencing.

DQA1*01:39 differs from DQA1*01:02:01:01 by one nucleotide substitution at position 49 in exon 1.

Characterization of the novel HLA-A*24:470 allele by next-generation sequencing.

A*24:470 differs from A*24:02:01:01 by one nucleotide substitution at position 46 in exon 1.

Characterization of the novel HLA-B*15:474 allele by next-generation sequencing.

B*15:474 differs from B*15:01:01:01 by one nucleotide substitution at position 923 in exon 5.

Characterization of the novel HLA-B*40:450 allele by next-generation sequencing.

B*40:450 differs from B*40:01:02:01 by one nucleotide substitution at position 5 in exon 1.

Characterization of the novel HLA-B*51:296 allele by next-generation sequencing.

B*51:296 differs from B*51:01:01:01 by one nucleotide substitution at position 1030 in exon 6.

Characterization of the novel HLA-DQB1*03:400N allele by next-generation sequencing.

DQB1*03:400N differs from DQB1*03:01:01:03 by one nucleotide insertion at position 535 in exon 3.

Characterization of the novel HLA-DRB1*01:107 allele by next-generation sequencing.

DRB1*01:107 differs from DRB1*01:01:01:01 by one nucleotide substitution at position 484 in exon 3.

Characterization of the novel HLA-B*44:476 allele by next-generation sequencing.

B*44:476 differs from B*44:03:01:01 by one nucleotide substitution at position 934 in exon 5.

Characterization of the novel HLA-DQB1*03:417 allele by next-generation sequencing.

DQB1*03:417 differs from DQB1*03:01:01:01 by one nucleotide substitution at position 179 in exon 2.

Characterization of the novel HLA-DRB1*11:260 allele by next-generation sequencing.

DRB1*11:260 differs from DRB1*11:03:01 by one nucleotide substitution at position 484 in exon 3.

Characterization of the novel HLA-C*06:283 allele by next-generation sequencing.

C*06:283 differs from C*06:02:01:01 by one nucleotide substitution at position 764 in exon 4.

Characterization of the novel HLA-B*44:452 allele by next-generation sequencing.

B*44:452 differs from B*44:02:01:01 by one nucleotide substitution at position 527 in exon 3.

Characterization of the novel HLA-A*32:134 allele by next-generation sequencing.

A*32:134 differs from A*32:01:01:01 by one nucleotide substitution at position 925 in exon 5.

Characterization of the novel HLA-DQB1*06:352 allele by next-generation sequencing.

DQB1*06:352 differs from DQB1*06:03:01:01 by one nucleotide substitution at position 668 in exon 4.

Characterization of the novel HLA-B*07:381 allele by next-generation sequencing.

HLA-B*07:381 differs from B*07:02:01:01 by one nucleotide substitution at position 1046 in exon 7.

Characterization of the novel HLA-B*07:385 allele by next-generation sequencing.

B*07:385 differs from B*07:02:01:01 by one nucleotide substitution at position 660 in exon 4.

Characterization of the novel HLA-A*11:349 allele by next-generation sequencing.

A*11:349 differs from A*11:01:01:01 by one nucleotide substitution at position 688 in exon 4.